PT - JOURNAL ARTICLE AU - Charmetant, Xavier AU - Espi, Maxime AU - Barba, Thomas AU - Ovize, Anne AU - Morelon, Emmanuel AU - Thaunat, Olivier TI - Predictive factors of response to 3<sup>rd</sup> dose of COVID-19 mRNA vaccine in kidney transplant recipients AID - 10.1101/2021.08.23.21262293 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.23.21262293 4099 - http://medrxiv.org/content/early/2021/08/30/2021.08.23.21262293.short 4100 - http://medrxiv.org/content/early/2021/08/30/2021.08.23.21262293.full AB - Only a minority of kidney transplant recipients (KTRs) develop protective neutralizing titers of anti-receptor binding domain of spike protein (RBD) IgG after two doses of mRNA COVID-19 vaccine. Administration of a third dose of mRNA vaccine to KTRs with sub-optimal response increase anti-RBD IgG titers but with high inter-individual variability. Patients with the higher response rate to the third dose of vaccine can be identified by the presence of low anti-RBD IgG titers and spike-specific CD4+ T cells in their circulation 14 days after the second dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementXC is supported by a funding from the Societe Francophone de Transplantation. ME is supported by the Hospices civils de Lyon and currently holds a poste accueil position funded by INSERM. OT is supported by the Etablissement Francais du Sang and the Fondation pour la Recherche Medicale (PME20180639518).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Institutional Review Board (approval number: 2020-A02918-31, Comite de Protection des Personnes Sud-Est I).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA